PRESS RELEASE published on 11/14/2023 at 12:45, 2 years 8 months ago Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE published on 10/16/2023 at 12:45, 2 years 9 months ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE published on 10/12/2023 at 12:45, 2 years 9 months ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 2 years 11 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 3 years ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 3 years ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 3 years 1 month ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
PRESS RELEASE published on 05/31/2023 at 12:40, 3 years 1 month ago NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
PRESS RELEASE published on 05/16/2023 at 12:45, 3 years 2 months ago NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
PRESS RELEASE published on 04/25/2023 at 12:45, 3 years 3 months ago NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
Published on 07/31/2026 at 08:00, 1 hour 6 minutes ago Caledonia Mining Corporation Plc Notification of Relevant Change to Significant Shareholder
Published on 07/31/2026 at 01:39, 7 hours 27 minutes ago Transition from OTCQB to Unsponsored OTC Quotation
Published on 07/30/2026 at 23:45, 9 hours 21 minutes ago Namibia Critical Metals Announces Completion of Japan's C$23 Million Earn-In and Formation of Strategic Joint Venture Company for the Lofdal Heavy Rare Earth Project
Published on 07/30/2026 at 23:01, 10 hours 5 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended June 30, 2026 and Management Changes
Published on 07/30/2026 at 23:00, 10 hours 6 minutes ago Eagle Plains Announces Approval of Warrant Expiry Extension
Published on 07/31/2026 at 08:10, 56 minutes ago Aquis Stock Exchange: Application for admission to trading
Published on 07/31/2026 at 08:00, 1 hour 6 minutes ago Transformation continues: CENIT shows increased profitability in the first half year 2026
Published on 07/31/2026 at 08:00, 1 hour 6 minutes ago PUMA Q2 2026 reflects reset measures and softer demand - Strong free cash flow - FY 2026 outlook confirmed
Published on 07/31/2026 at 08:57, 9 minutes ago FIRST-HALF 2026 RESULTS : Successful launch of the new strategic plan, activity maintained at the very high level of 2025 and solid results
Published on 07/31/2026 at 08:32, 34 minutes ago Completion of the acquisition of the Scholz Recycling Group
Published on 07/31/2026 at 08:21, 45 minutes ago Edenred and Abry Partners forge a strategic partnership to support the next phase of Edenred Pay North America’s development
